 LEIDEN, Netherlands and CAMBRIDGE, Mass., April 05, 2021 GLOBE NEWSWIRE -- ProQR Therapeutics N.V. Nasdaq: PRQR, a company dedicated to changing lives through the creation of transformative RNA therapies for inherited retinal diseases IRDs, today announced the closing of its previously announced underwritten public offering of 13,846,154 ordinary shares at a price to the public of 6.50 per share. All of the shares were offered by ProQR. The closing included the full exercise of the underwriters option to purchase up to 2,076,923 additional ordinary shares at the public offering price, less underwriting discounts and commissions. Gross proceeds from the offering totaled approximately 103.5 million, before deducting underwriting discounts and commissions and offering expenses. 